Jason M Wagner

US Patent:

8354414, Jan 15, 2013

Filed:

Nov 4, 2010

Appl. No.:

12/939527

Inventors:

Edward R. Bacon - Audubon PA, US
Thomas Bailey - Phoenixville PA, US
Nadine C. Becknell - Coatesville PA, US
Diane E. Gingrich - Downingtown PA, US
Greg A. Hostetler - Newark DE, US
Robert L. Hudkins - Chester Springs PA, US
Keith S. Learn - Perkiomenville PA, US
Jason C. Wagner - Coatesville PA, US

Assignee:

Cephalon, Inc - Frazer PA

International Classification:

C07D 239/70
C07D 471/04
A61K 31/517
A61K 31/519
C07D 239/72
C07D 239/84
C07D 239/78
C07D 487/04

US Classification:

5142581, 5142611, 51426411, 5142641, 5142662, 544253, 544254, 544279, 544284

Abstract:

The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I):.

US Patent:

20070281949, Dec 6, 2007

Filed:

May 14, 2007

Appl. No.:

11/803320

Inventors:

Edward Bacon - Audubon PA, US
Thomas Bailey - Phoenixville PA, US
Nadine Becknell - Coatesville PA, US
Diane Gingrich - Downingtown PA, US
Greg Hostetler - Newark DE, US
Robert Hudkins - Chester Springs PA, US
Keith Learn - Perkiomenville PA, US
Jason Wagner - Coatesville PA, US

Assignee:

Cephalon, Inc. - Frazer PA

International Classification:

A61K 31/519
A61K 31/517
C07D 487/02
C07D 403/02

US Classification:

514258100, 514261100, 514262100, 514264110, 514266200, 544262000, 544254000, 544279000, 544284000

Abstract:

The present invention is related to chemical compositions, processes for the preparation thereof and uses of the composition. Particularly, the present invention relates to compositions that include substituted heterobicyclic pyrimidines of Formula (I): wherein R, R, R, R, R, X, W, and ring A are as defined herein; pharmaceutical compositions of substituted heterobicyclic pyrimidines of Formula (I); and their use in the treatment of chronic neurodegenerative diseases, neurotraumatic diseases, depression and/or diabetes. More particularly, the present invention relates to substituted pyrazolopyrimidines of Formula (I).

US Patent:

20090221555, Sep 3, 2009

Filed:

Oct 23, 2007

Appl. No.:

12/162851

Inventors:

Gulzar Ahmed - Voorhees NJ, US
Adolph Bohnstedt - Burlington NJ, US
Henry Joseph Breslin - Lansdale PA, US
Jason Burke - Charlottesville VA, US
Matthew A. Curry - Coatesville PA, US
James L. Diebold - Norristown PA, US
Bruce Dorsey - Ambler PA, US
Benjamin J. Dugan - Glen Mills PA, US
Daming Feng - East Windsor NJ, US
Diane E. Gingrich - Downingtown PA, US
Tao Guo - Dayton NJ, US
Keith S. Learn - Perkiomenville PA, US
Joseph G. Lisko - Glenmoore PA, US
Eugen Mesaros - Philadelphia PA, US
Karen Milkiewicz - Exton PA, US
Gregory R. Ott - Media PA, US
Jonathan Parrish - New York NY, US
Jay P. Theroff - West Chester PA, US
Tho V. Thieu - Ambler PA, US
Rabindranath Tripathy - Churchville PA, US
Theodore L. Underiner - Malvern PA, US
Jason C. Wagner - Coatesville PA, US
Linda Weinberg - Villanova PA, US
Gregory J. Wells - West Chester PA, US
Ming You - Plainsboro NJ, US
Craig A. Zificsak - Downingtown PA, US

Assignee:

Cephalon, Inc. - Frazer PA
Pharmacopeia Drug Discovery, Inc. - Cranbury NJ

International Classification:

A61K 31/55
C07D 239/02
A61K 31/505
C07D 403/00
C07D 413/14
A61K 31/5377
C07D 413/00
C07D 403/14

US Classification:

51421706, 544323, 514275, 540601, 5142355, 544122

Abstract:

The present invention provides a compound of formula I or II or a pharmaceutically acceptable salt form thereof, wherein R, R, R, R, R, A, A, A, A, and A, are as defined herein. The compounds of formula I or II have ALK and/or c-Met inhibitory activity, and may be used to treat proliferative disorders.

US Patent:

20140323435, Oct 30, 2014

Filed:

May 22, 2014

Appl. No.:

14/285007

Inventors:

- London, GB
- Frazer PA, US
Emma L. Morris - Biggleswade, GB
Gregory R. Ott - Media PA, US
Jonathan R.A. Roffey - Reading, GB
Christelle N. Soudy - London, GB
Jason C. Wagner - Coatesville PA, US

Assignee:

Cancer Research Technology Limited - London
Cephalon, Inc. - Frazer PA

International Classification:

C07D 495/04
C07D 495/20
C07F 7/08
C07D 495/14

US Classification:

514 63, 544250, 514267, 51425216, 540575, 514218, 544278, 5142581, 544230, 51421021, 544229, 51425505, 544117, 5142342

Abstract:

The present application provides a compound of formula (I)or a salt thereof, wherein R, R, R, R, R, R, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.